Patient P-02224
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
82%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 No meaningful change — Dietary Support Protocol NP-02
- Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 73 GI-04 recommended — GI Support Protocol GI-04
- Day 74 Patient accepted — Started GI-04 in the companion
- Day 82 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 69.
Primary contributors, last 14 days
- Inflammatory activity+8
- Toxicity+5
- Nutritional resilience-4
- GI instability+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: no meaningful change
- GI Support Protocol GI-04Day 73Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
82%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 30/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 68
- WearableHRV 36 ms, trending down
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 65 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 56
- Autonomic recovery ↑20
- Wearable3,204 steps/day
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.5 · butyrate capacity 30/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 34 ms
- Sleep
- 6.6 h
- Steps
- 3,392
- Resting HR
- 68 bpm
Daily log: GI score 65, nutritional resilience 31, adherence 43.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02048 | 17% | S02 | — | — | 77 |
| P-02115 | 18% | S14 | GI-04 | improved | 75 |
| P-02575 | 19% | S14 | ME-01 | improved | 73 |
| P-02659 | 20% | S09 | — | — | 69 |
| P-02591 | 26% | S13 | — | — | 68 |
| P-02265 | 24% | S07 | GI-04 | no change | 67 |
| P-02530 | 25% | S07 | — | — | 67 |
| P-02436 | 17% | S05 | — | — | 67 |
| P-02367 | 27% | S03 | — | — | 67 |
| P-02309 | 21% | S09 | — | — | 67 |
| P-02334 | 23% | S04 | GI-04 | improved | 66 |
| P-02109 | 17% | S04 | — | — | 66 |